Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00911859
Registration number
NCT00911859
Ethics application status
Date submitted
29/05/2009
Date registered
2/06/2009
Date last updated
18/11/2014
Titles & IDs
Public title
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Query!
Scientific title
A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma
Query!
Secondary ID [1]
0
0
CNTO328MMY2001
Query!
Secondary ID [2]
0
0
CR015901
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Siltuximab11 mg/kg
Treatment: Drugs - Siltuximab 8.3 mg/kg or 11 mg/kg
Treatment: Drugs - Velcade (bortezomib)
Treatment: Drugs - Velcade (bortezomib)
Treatment: Drugs - Melphalan
Treatment: Drugs - Melphalan
Treatment: Drugs - Prednisone
Treatment: Drugs - Prednisone
Treatment: Drugs - Velcade (bortezomib)
Treatment: Drugs - Melphalan
Treatment: Drugs - Prednisone
Experimental: Part 1: VMP+Siltuximab 11 mg/kg - Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
Experimental: Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg - Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
Active Comparator: Part 2, Arm B: VMP - Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
Treatment: Drugs: Siltuximab11 mg/kg
Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
Treatment: Drugs: Siltuximab 8.3 mg/kg or 11 mg/kg
Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
Treatment: Drugs: Velcade (bortezomib)
Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
Treatment: Drugs: Velcade (bortezomib)
Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
Treatment: Drugs: Melphalan
Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
Treatment: Drugs: Melphalan
Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
Treatment: Drugs: Prednisone
Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
Treatment: Drugs: Prednisone
Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
Treatment: Drugs: Velcade (bortezomib)
Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
Treatment: Drugs: Melphalan
Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
Treatment: Drugs: Prednisone
Participants will take prednisone 60 mg/m2 orally according to the package insert.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria
Query!
Assessment method [1]
0
0
CR was assessed using EMBT criteria: disappearance of the original monoclonal paraprotein from the blood and urine on at least 2 determinations for a minimum of 6 weeks by immunofixation studies, <5% plasma cells in the bone marrow on at least 1 determination, if skeletal survey is available: no increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response), disappearance of soft tissue plasmacytomas for at least 6 weeks.
Query!
Timepoint [1]
0
0
Up to disease progression, approximately 3 years
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria
Query!
Assessment method [1]
0
0
CR or PR was assessed using EBMT criteria. CR: disappearance of the original monoclonal paraprotein from the blood and urine on at least 2 determinations for a minimum of 6 weeks by immunofixation studies, <5% plasma cells in the bone marrow on at least 1 determination, if skeletal survey is available: no increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response), disappearance of soft tissue plasmacytomas for at least 6 weeks; PR: >=50% reduction in the level of serum monoclonal paraprotein for at least 2 determinations 6 weeks apart, if present, reduction in 24-hour urinary light chain excretion by either >=90% or to <200 mg for at least 2 determinations 6 weeks apart, >=50% reduction in the size of soft tissue plasmacytomas (by clinical or radiographic examination) for at least 6 weeks, if skeletal survey is available: no increase in size or number of lytic bone lesions
Query!
Timepoint [1]
0
0
Up to disease progression, approximately 3 years
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria
Query!
Assessment method [2]
0
0
sCR was assesses by IMWG Criteria: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, <=5% plasma cells in bone marrow, normal free light chain ratio, absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. sCR is a CR that has been confirmed by immunofixation + free light chain assay + either bone marrow immunohistochemistry or immunofluorescence
Query!
Timepoint [2]
0
0
Up to disease progression, approximately 3 years
Query!
Secondary outcome [3]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [3]
0
0
PFS was defined as the time between randomization and either disease progression or death, whichever occurred first.
Query!
Timepoint [3]
0
0
From the date of randomization until disease progression or death, whichever occurred first, as assessed up to the last efficacy assessment for disease progression (approximately 3 years)
Query!
Secondary outcome [4]
0
0
1-year Progression-Free Survival (PFS) Rate
Query!
Assessment method [4]
0
0
The 1-year PFS rate was defined as the percentage of participants surviving 1 year after randomization without disease progression or death.
Query!
Timepoint [4]
0
0
1 year
Query!
Secondary outcome [5]
0
0
Duration of Response (DOR)
Query!
Assessment method [5]
0
0
DOR was defined as length from the earliest date a participant achieved a complete response (CR) or partial response (PR) to either date for disease progression (including relapse from CR) or the censoring date for progressive disease. Responders without disease progression were censored at the last efficacy assessment for disease progression.
Query!
Timepoint [5]
0
0
From the date participants achieved CR or PR to either date for disease progression (including relapse from CR) or the censoring date for progressive disease, as assessed Up to 30 days after last dose of study medication
Query!
Secondary outcome [6]
0
0
1-year Survival Rate
Query!
Assessment method [6]
0
0
Percentage of participants who are alive at the end of year 1 after randomization
Query!
Timepoint [6]
0
0
1 year
Query!
Secondary outcome [7]
0
0
Overall Survival
Query!
Assessment method [7]
0
0
Overall survival is defined as the time interval in days between the date of randomization and the participant's death from any cause.
Query!
Timepoint [7]
0
0
From the date of randomization till the date of death, as assessed up to the end of study (approximately 3 years)
Query!
Secondary outcome [8]
0
0
Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)
Query!
Assessment method [8]
0
0
Global health status/quality of life is a subscale of the EORTC QOL C30, which comprises two questions related to overall health/quality of life during the past week. The raw score to each question ranged from 1 (very poor) to 7 (excellent). The raw mean score of health status/quality of life subscale is calculated for each participant and a linear transformation applied to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") health and quality of life.
Query!
Timepoint [8]
0
0
Baseline (Day 1 predose) and Cycle 9 (Week 54)
Query!
Eligibility
Key inclusion criteria
- Confirmed diagnosis of previously untreated multiple myeloma and not a candidate for
high dose chemotherapy with stem cell transplantation
- Eastern cooperative oncology group performance status score of less than or equal to 2
- Measurable secretory disease, defined as either serum monoclonal paraprotein greater
than or equal to 1 g/dL or urine monoclonal protein greater than 200 mg/24 hours
- Adequate laboratory results that will be confirmed by a study physician
- Agrees to protocol-defined use of effective contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Diagnosed with primary amyloidosis, asymptomatic or smoldering multiple myeloma or
monoclonal gammopathy of undetermined significance
- Diagnosed with Waldenstrom's disease, or other conditions in which IgM M-protein is
present in the absence of a clonal plasma cell infiltration with lytic bone lesions
- Received prior or current systemic therapy or stem cell transplantation for multiple
myeloma
- Peripheral neuropathy or neuropathic pain (Grade 2 or higher)
- Received radiation therapy, plasmapheresis or surgery within 14 days
- Transplanted solid organ, with the exception of a corneal transplant
- Serious concurrent illness or history of uncontrolled heart disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
118
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Massachusetts
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
North Carolina
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Pennsylvania
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Bordeaux Cedex
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Montpellier
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Strasbourg
Query!
Country [8]
0
0
India
Query!
State/province [8]
0
0
Ahmedabad
Query!
Country [9]
0
0
India
Query!
State/province [9]
0
0
Calicut
Query!
Country [10]
0
0
India
Query!
State/province [10]
0
0
Hyderabad N/A
Query!
Country [11]
0
0
India
Query!
State/province [11]
0
0
Jaipur
Query!
Country [12]
0
0
India
Query!
State/province [12]
0
0
Mumbai
Query!
Country [13]
0
0
Israel
Query!
State/province [13]
0
0
Afula
Query!
Country [14]
0
0
Israel
Query!
State/province [14]
0
0
Haifa
Query!
Country [15]
0
0
Israel
Query!
State/province [15]
0
0
Jerusalem
Query!
Country [16]
0
0
Israel
Query!
State/province [16]
0
0
Petah Tikva
Query!
Country [17]
0
0
Israel
Query!
State/province [17]
0
0
Ramat-Gan
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Seoul
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Bialystok
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Chorzów
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Gdynia
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Lodz
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Wroclaw
Query!
Country [24]
0
0
Romania
Query!
State/province [24]
0
0
Baia Mare
Query!
Country [25]
0
0
Romania
Query!
State/province [25]
0
0
Brasov
Query!
Country [26]
0
0
Romania
Query!
State/province [26]
0
0
Iasi
Query!
Country [27]
0
0
Russian Federation
Query!
State/province [27]
0
0
Arkhangelsk
Query!
Country [28]
0
0
Russian Federation
Query!
State/province [28]
0
0
Moscow N/A
Query!
Country [29]
0
0
Russian Federation
Query!
State/province [29]
0
0
Nizhni Novgorod
Query!
Country [30]
0
0
Russian Federation
Query!
State/province [30]
0
0
St. Petersburg
Query!
Country [31]
0
0
Singapore
Query!
State/province [31]
0
0
Singapore
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Barcelona
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Madrid
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Murcia N/A
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Salamanca
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab)
when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with
VMP alone in participants with multiple myeloma (a type of cancer that affects the blood and
bone marrow).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00911859
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development L.L.C Clinical Trial
Query!
Address
0
0
Janssen Research & Development L.L.C
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00911859
Download to PDF